Deflazacort (Calcort) is a glucocorticoid drug, and its active ingredient, Deflazacort, exerts anti-inflammatory and immunosuppressive effects.

How Effective is Deflazacort (Calcort) in Treatment?

Main Therapeutic Effects

As a glucocorticoid, deflazacort has shown good efficacy in the treatment of various inflammatory and autoimmune diseases.

By inhibiting the activation and migration of inflammatory cells and reducing the release of inflammatory mediators, the drug achieves the goal of controlling inflammatory responses.

In the field of muscle diseases, deflazacort is particularly suitable for the treatment of Duchenne muscular dystrophy (DMD), as it can significantly delay disease progression and improve muscle function.

Compared with other glucocorticoids, deflazacort may cause fewer adverse reactions while maintaining its therapeutic effects.

Applicable Populations for Deflazacort (Calcort)

Patients with Duchenne Muscular Dystrophy (DMD)

Deflazacort oral suspension (22.75 mg/mL) has been approved by the FDA for the treatment of patients with DMD.

This drug can delay the degeneration of muscle function and improve patients' quality of life.

Patients with Other Inflammatory Diseases

In addition to DMD, deflazacort can also be used to treat other inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.

However, it should be noted that these indications may vary by region.

Administration in Special Populations

Pediatric Patients: DMD patients usually start using the drug during childhood.

Elderly Patients: Dose adjustment may be required.

Patients with Hepatic or Renal Impairment: The drug should be used with caution, and dose adjustment may be necessary.

Pregnant and Lactating Women: The drug should be used only after doctors have strictly evaluated the risk-benefit ratio.

Medication Monitoring for Deflazacort (Calcort)

Pre-Treatment Assessment

Conduct a comprehensive assessment of the patient's baseline condition.

Measure height and weight (especially for pediatric patients).

Perform a baseline bone mineral density test (for patients on long-term medication).

Conduct an ophthalmic examination (to assess the risk of cataracts).

Measure blood glucose and blood pressure.

Routine Monitoring

Regularly assess therapeutic effects and disease progression.

Monitor growth and development indicators (for pediatric patients).

Regularly measure blood pressure and blood glucose.

Safety Monitoring

Monitor bone mineral density (for patients on long-term medication).

Conduct regular ophthalmic examinations.

Monitor electrolyte balance.

Monitor for signs of infection.